




Detecting Atrial Fibrillation Early at Home

Early detection and treatment of AFib reduces risk of stroke by 66%¹

Atrial Fibrillation (AFib): — It can lead to:²

the most prevalent arrhythmia



lifetime risk of **26%** ♂ **23%** ♀ affecting **33,5** million people worldwide^{5,6}

AFib can be classified into 4 varieties:⁷

- Paroxysmal** < 1 week
- Persistent** > 1 week
- Long-standing Persistent** ≥ 12 months
- Permanent** can't be restored

What people might notice when they have AFib:

Arrhythmia — Heart palpitations — Chest pain

Shortness of breath — Fatigue — Dizziness or fainting

However

50-87% of patients are initially asymptomatic⁷

Blood clots

Ischemic stroke
(20% of all strokes are due to AF)

Heart failure

Premature death

Heart-related complications

Increased risk of^{3,4}

stroke
4-5 times

Life-threatening complications and other diseases

5 times

Risk factors and underlying comorbidities⁸



Relationship between hypertension and AFib^{10, 11}



60-80%

In 60-80% of AFib cases hypertension is present



1,8-2×
higher risk

Individuals with hypertension and AFib have a 1.8-to 2-fold higher risk of stroke than those without hypertension

Simultaneously monitoring ECG and BP readings is crucial for reducing morbidity and mortality due to AFib

Recommendations from the ESC Guidelines 2020⁷



Lifestyle changes and weight loss in patients with obesity.



Opportunistic screening for AFib in elderly and hypertensive patients.



Definite diagnosis of AFib in screen-positive cases: only after physician reviews the single-lead ECG recording of ≥30 s or 12-lead ECG

ECG test is the easiest and most definitive method to detect AFib.

Recent advances finally allow patients to monitor their heart from home • detecting their risk earlier

OMRON Complete

A 2-in-1 home blood pressure monitor with a 1-lead ECG function



OMRON Complete: an accurate and easy blood pressure monitor with ECG recording



Early detection by routine recording electrocardiogram (ECG) measurements



Instant and clear ECG results



Learn more and discover OMRON Complete

Helping your patients to lead more fulfilling and active lives. Making sure you can recommend clinically validated medical devices for their home care, making zero compromise on health.

References

1. Lei N, et al. Hybrid Decision Support to Monitor Atrial Fibrillation for Stroke Prevention. Int J Environ Res Public Health. 2021 Jan 19;18(2):813
2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847
3. NHS. Atrial Fibrillation, 2018. Available at <https://www.nhs.uk/conditions/atrial-fibrillation/complications/>. Last accessed May 2019.
4. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al. (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease.
5. Lloyd-jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-6.
6. Morillo, Carlos A et al. "Atrial fibrillation: the current epidemic." Journal of geriatric cardiology : JGC vol. 14,3 (2017): 195-203. doi:10.11909/j.issn.1671-5411.2017.03.011.
7. Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal (2020) 00, 1-126. doi:10.1093/eurheartj/ehaa612
8. Brandes, Axel et al. "Risk Factor Management in Atrial Fibrillation." Arrhythmia & electrophysiology review vol. 7,2 (2018): 118-127. doi:10.15420/aer.2018.18.2
9. Esato M, Chun YH, An Y, et al. Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry. Chest.2017;152(6):1266-1275.
10. Howard, Patricia A. "Guidelines for stroke prevention in patients with atrial fibrillation." Drugs 58,6 (1999): 997-1009.
11. Verdecchia, Paolo, Fabio Angeli, and Gianpaolo Reboldi. "Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies." Circulation Research 122,2 (2018): 352-368

OMRON

PM-00394-01-22-OHE